reMYND out-licenses diabetes candidate to Novo

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) gained exclusive, worldwide rights from reMYND N.V. (Leuven, Belgium) to develop and commercialize ReS39, which reMYND believes has the potential to be a disease-modifying treatment for diabetes.

reMYND received an undisclosed upfront payment and is eligible for €350 million ($412.8 million) in milestones and research payments, plus undisclosed royalties...